Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Krahl, A."'
Autor:
Christian Jakob, Christian Junghanss, Sebastian Schwind, Volker Schmidt, Niklas Zojer, Kolija Reifenrath, Andreas Hochhaus, Christoph Kahl, Dietger Niederwieser, Haifa Kathrin Al-Ali, Georg Maschmeyer, Thomas Heinicke, Herbert G. Sayer, Norma Peter, Rainer Krahl, Thomas Fischer, Sebastian Scholl, Axel Florschütz, Ute Hegenbart, Michael Cross, Hans-Heinrich Wolf, Christian Niederwieser
Publikováno v:
Blood. 134:1358-1358
Introduction: Outcome of patients (pts) with refractory AML or following relapse is considered dismal and usually reported as refractory/relapsed. Here we analyzed long term outcome of refractory and relapsing pts separately over a 10 year (y) period
Autor:
Dietger Niederwieser, Thomas Friedrich, Michael W. Deininger, Christina Franke, Evelin Hennig, Thomas Bumm, Erika Schmidt, Knut Krohn, Patricia Shepherd, Christel Müller, R. Krahl, Sabine Leiblein, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 101:1941-1949
Chronic myelogenous leukemia (CML) is characterized by the presence of a Bcr-Abl fusion protein with deregulated tyrosine kinase activity that is required for maintaining the malignant phenotype. Imatinib, a selective inhibitor ofBcr-Abl, induces maj
Autor:
Martin Hildebrandt, Markus Y. Mapara, Peter Reichardt, Bernd Dörken, Ralf C. Bargou, Dorothea Krahl, Ida J. Körner
Publikováno v:
Blood. 89:337-344
We studied the efficiency of indirect tumor cell purging via enrichment of CD34+ hematopoietic progenitor cells from leukapheresis products (LP) in breast cancer patients based on immunomagnetic selection of CD34+ cells. Detection of tumor cells was
Autor:
Mathias Haenel, Song-Yau Wang, Susann Schultze, Nadja Jaekel, Christian Jakob, Regina Herbst, Georg Maschmeyer, Dietger Niederwieser, Oana Brosteanu, Haifa Kathrin Al-Ali, Rainer Krahl, Karolin Hubert
Publikováno v:
Blood. 126:1346-1346
The prognosis of AML in patients (pts) >60 years (y) is poor and there is no universally accepted standard approach. After induction chemotherapy (IC), a complete remission (CR+CRi) rate of 56.4% and a mortality of 21% at day (d) 90 are expected (Nie
Autor:
Haifa Kathrin Al-Ali, Thomas Heinicke, Herbert G. Sayer, Hans-Heinrich Wolf, Kolja Reifenrath, Christian Junghanss, Sebastian Scholl, Rainer Krahl, Norma Peter, Thomas Fischer, Antje Schulze, Niklas Zojer, Christian Jakob, Georg Maschmeyer, Christoph Kahl, Ute Hegenbart, Axel Florschütz, Andreas Hochhaus, Dietger Niederwieser, Detlev Hähling
Publikováno v:
Blood. 124:3666-3666
Purpose: To define prognostic factors for overall survival in adult patients (pts) with relapsed acute myeloid leukemia (AML). Introduction: Prognostic factors for overall survival after AML relapse are poorly defined. Here, we investigate patient an
Autor:
Norma Peter, Antje Schulze, Christoph Kahl, Detlev Hähling, Hans-Heinrich Wolf, Thomas Heinicke, Herbert G. Sayer, Ute Kreibich, Andreas Hochhaus, Georg Maschmeyer, Mathias Hänel, Erika Kettner, Haifa Kathrin Al-Ali, Rainer Krahl, Sebastian Scholl, Michael Herold, Dietrich Kämpfe, Thomas Fischer, Christian Junghanss, Lutz Uharek, Dietger Niederwieser
Publikováno v:
Blood. 124:3664-3664
The incidence of acute myeloid leukemia (AML) is age-dependent with the majority of patients (pts) being older than 60 years at diagnosis. Treatment of these pts needs to be well balanced between sufficient efficacy and tolerable toxicity. Here, we r
Autor:
Hans-Heinrich Wolf, Norma Peter, Carsten Hirt, Detlev Haehling, Kolja Reifenrath, Bernhard Opitz, Vladan Vucinic, Christian Jakob, Georg Maschmeyer, Peter Dreger, Alwin Kraemer, Dietger Niederwieser, Ute Kreibich, Haifa Kathrin Al-Ali, Thomas Heinicke, Herbert G. Sayer, Antje Schulze, Niklas Zojer, Christoph Kahl, Simone Heyn, Axel Florschütz, Ute Hegenbart, Wolfram Pönisch, Thomas Fischer, Rainer Krahl, Andreas Hochhaus, Christian Junghanss, Sebastian Scholl
Publikováno v:
Blood. 124:280-280
Treatment of elderly patients with AML remains challenging. While increasing doses of induction and consolidation chemotherapy have failed to improve outcome, efforts to decrease relapse rates using the graft-versus-leukemia effect have shown promisi
Autor:
Thomas Heinicke, Rainer Krahl, Christian Jakob, Christoph Kahl, Hans-Heinrich Wolf, Ute Kreibich, Frank Rothmann, Detlev Hähling, Manfred Schulze, Ulrich Wedding, Ute Hegenbart, Carsten Hirt, Norma Peter, Bernhard Opitz, Antje Schulze, Christian Junghanss, Andreas Hochhaus, Thomas Fischer, Dietger Niederwieser, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 122:1409-1409
Purpose In patients with relapsed acute myeloid leukemia (AML) > 60 years of age we analyzed age at relapse, interval from first complete remission (CR1) to relapse, cytogenetic risk at initial diagnosis, prior allogeneic stem cell transplantation (a
Autor:
Nadja Jaekel, Cornelia Becker, Leanthe Braunert, Thoralf Lange, Rainer Krahl, Georg Franke, Dietger Niederwieser, Jeanett Edelmann, Wolfram Poenisch, Sabine Leiblein, Claudia Nehring, Haifa Kathrin Al-Ali
Publikováno v:
Blood. 118:3065-3065
Abstract 3065 Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity-conditioning (RIC) is a curative therapeutic option in elderly patients with AML. Yet, hematological relapse (HR) and non-relapse mortality (NRM) remain maj
Autor:
Gerhard Behre, Cornelia Becker, Simona Iacobelli, Wolfram Pönisch, Christian Pfrepper, Thoralf Lange, Ann-Kathrin Eisfeld, Karin Hebenstreit, Haifa Kathrin Al-Ali, Dietger Niederwieser, Rainer Krahl
Publikováno v:
Blood. 118:4532-4532
Abstract 4532 Introduction: In an unicenter analysis we investigated the impact of allogeneic hematopoietic cell transplantation (RIC-HCT) after reduced intensity conditioning on the kinetics of engraftment and predictor of outcome in 50 patients wit